STOCK TITAN

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Iveric Bio, Inc. (NASDAQ: ISEE) announced on April 3, 2023, the grant of equity-based awards to nine new non-executive employees. These inducement grants were made under the Company’s 2019 Inducement Stock Incentive Plan and consist of non-statutory stock options for 166,000 shares and 27,000 restricted stock units. The stock options have an exercise price of $26.49 per share and a vesting schedule spanning four years, with 25% vesting on April 3, 2024. Iveric Bio focuses on developing treatments for retinal diseases and aims to improve patient outcomes in this area.

Positive
  • Issuing inducement grants can attract talent, which may enhance company innovation and performance.
  • The exercise price for stock options is aligned with the company's market value on the grant date.
Negative
  • None.

PARSIPPANY, N.J.--(BUSINESS WIRE)-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on April 3, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees. These inducement grants were approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The inducement grants consisted of non-statutory stock options to purchase 166,000 shares of the Company’s common stock and 27,000 restricted stock units for shares of the Company’s common stock.

The stock options have an exercise price of $26.49 per share, equal to the closing price of Iveric Bio’s common stock on April 3, 2023. The stock option grants have a ten-year term and vest over four years, with 25% of the shares underlying the options vesting on April 3, 2024 and an additional 2.0833% of the shares underlying the options vesting at the end of each successive month thereafter. A tranche of 4,500 restricted stock units vests with respect to 100% of the shares underlying the units on July 1, 2023. A tranche of 3,500 restricted stock units vests with respect to 50% of the shares underlying the units on July 1, 2023 and the remaining 50% of the shares underlying the units on October 1, 2023. A tranche of 500 restricted stock units vests with respect to 100% of the shares underlying the units on October 1, 2023. A tranche of 18,500 restricted stock units vests with respect to 25% of the shares underlying the units on each of April 1, 2024, April 1, 2025, April 1, 2026 and April 1, 2027. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.

Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

ISEE-G

Investor / Media Contact:

Iveric Bio

Kathy Galante

Senior Vice President, Investor Relations

kathy.galante@ivericbio.com

Media Contact:

Jeannie Neufeld

Senior Director, Public Relations and Communications

Jeannie.neufeld@ivericbio.com

Source: IVERIC bio, Inc.

FAQ

What equity-based awards did Iveric Bio grant in April 2023?

Iveric Bio granted non-statutory stock options for 166,000 shares and 27,000 restricted stock units to nine new employees.

What is the exercise price for the stock options granted by Iveric Bio?

The exercise price for the stock options is $26.49 per share, equal to the closing price on April 3, 2023.

What is the vesting schedule for the stock options issued by Iveric Bio?

The stock options vest over four years, with 25% vesting on April 3, 2024, and an additional 2.0833% vesting monthly thereafter.

What is Iveric Bio's focus area in biopharmaceuticals?

Iveric Bio is focused on developing innovative treatments for retinal diseases.

ISEE

NASDAQ:ISEE

ISEE Rankings

ISEE Latest News

ISEE Stock Data

5.51B
136.61M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York